| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mona Boules, Paul Fredrickson, Elliott Richelso. Bioactive analogs of neurotensin: focus on CNS effects. Peptides. vol 27. issue 10. 2006-11-20. PMID:16882457. |
it is closely associated anatomically with dopaminergic and other neurotransmitter systems, and evidence supports a role for nt agonists in the treatment of various neuropsychiatric disorders. |
2006-11-20 |
2023-08-12 |
Not clear |
| Mona Boules, Paul Fredrickson, Elliott Richelso. Neurotensin agonists as an alternative to antipsychotics. Expert opinion on investigational drugs. vol 14. issue 4. 2006-11-14. PMID:15882113. |
in brain, this peptide is prominently associated anatomically with dopaminergic, as well as other neurotransmitter systems. |
2006-11-14 |
2023-08-12 |
Not clear |
| Spiros Konitsioti. Novel pharmacological strategies for motor complications in Parkinson's disease. Expert opinion on investigational drugs. vol 14. issue 4. 2006-11-14. PMID:15882115. |
the nonphysiological, pulsatile stimulation produced by most currently available dopaminergic therapies triggers a complicated series of responses resulting in the dysregulation of glutamate receptors and many other neurotransmitter systems on striatal neurons. |
2006-11-14 |
2023-08-12 |
Not clear |
| Ubaldo Bonuccelli, Paolo Del Dott. New pharmacologic horizons in the treatment of Parkinson disease. Neurology. vol 67. issue 7 Suppl 2. 2006-10-30. PMID:17030738. |
the nonphysiologic pulsatile stimulation of striatal dopamine receptors, produced by the currently available dopaminergic drugs, may trigger a dysregulation of many neurotransmitter systems within the basal ganglia, mainly localized on medium spiny striatal neurons. |
2006-10-30 |
2023-08-12 |
Not clear |
| Bin Li. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. The AAPS journal. vol 8. issue 3. 2006-10-24. PMID:17025278. |
parkinson's disease (pd) is a debilitating movement disorder resulting from a progressive degeneration of the nigrostriatal dopaminergic pathway and depletion of neurotransmitter dopamine in the striatum. |
2006-10-24 |
2023-08-12 |
Not clear |
| W Michael Caudle, Jason R Richardson, Kristin C Delea, Thomas S Guillot, Minzheng Wang, Kurt D Pennell, Gary W Mille. Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity. Toxicological sciences : an official journal of the Society of Toxicology. vol 92. issue 2. 2006-09-29. PMID:16702228. |
the observed reductions appear to be specific to the dat populations located in the striatum, as no change was observed in other dopaminergic brain regions or to other neurotransmitter transporters present in the striatum. |
2006-09-29 |
2023-08-12 |
human |
| Chandrashekhar Deshpande, Ashish Dhir, S K Kulkarn. Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: apomorphine-induced stereotypic behavior in mice. Pharmacology. vol 77. issue 1. 2006-09-26. PMID:16569938. |
among the various neurotransmitter systems implicated in the mechanism of action of ascorbic acid (vitamin c), the relationship between the dopaminergic system and ascorbic acid is not particularly clear. |
2006-09-26 |
2023-08-12 |
mouse |
| Paul D Acton, Andrew Newber. Artificial neural network classifier for the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. Physics in medicine and biology. vol 51. issue 12. 2006-09-22. PMID:16757862. |
imaging the dopaminergic neurotransmitter system with positron emission tomography (pet) or single photon emission tomography (spect) is a powerful tool for the diagnosis of parkinson's disease (pd). |
2006-09-22 |
2023-08-12 |
human |
| Melanie Hamann, Roger Raymond, Suneel Varughesi, José N Nobrega, Angelika Richte. Acetylcholine receptor binding and cholinergic interneuron density are unaltered in a genetic animal model of primary paroxysmal dystonia. Brain research. vol 1099. issue 1. 2006-09-19. PMID:16764832. |
in fact, numerous pharmacological, neurochemical, immunohistochemical and electrophysiological investigations in the dt(sz) hamsters, a unique rodent model of age-dependent primary paroxysmal dystonia, revealed alterations within the basal ganglia, particularly of the gabaergic and dopaminergic neurotransmitter systems. |
2006-09-19 |
2023-08-12 |
Not clear |
| Caroline H Williams-Gray, Thomas Foltynie, Simon J G Lewis, Roger A Barke. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS drugs. vol 20. issue 6. 2006-09-05. PMID:16734499. |
deficits in neurotransmitter systems provide more obvious therapeutic targets and dysfunction of dopaminergic, cholinergic, noradrenergic and serotonergic systems have all been implicated; these may each underlie different features of parkinson's disease dementia, perhaps explaining some of the heterogeneity of the syndrome. |
2006-09-05 |
2023-08-12 |
Not clear |
| Bart Scholtissen, Ronald Deumens, Albert F G Leentjens, Christoph Schmitz, Arjan Blokland, Harry W M Steinbusch, Jos Prickaert. Functional investigations into the role of dopamine and serotonin in partial bilateral striatal 6-hydroxydopamine lesioned rats. Pharmacology, biochemistry, and behavior. vol 83. issue 2. 2006-08-14. PMID:16504275. |
in parkinson's disease (pd), several neurotransmitter systems, such as the dopaminergic and serotonergic system, show signs of degeneration. |
2006-08-14 |
2023-08-12 |
rat |
| Goutam Chandra, Prasanta K Gangopadhyay, Karuppagounder S Senthil Kumar, Kochupurackal P Mohanakuma. Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats. Brain research. vol 1075. issue 1. 2006-07-31. PMID:16487496. |
neurotransmitter levels in the serotonergic perikarya or terminals were unaltered 19 days following intraraphe infusion of homocysteine, which suggested the specificity of its action to dopaminergic neurons. |
2006-07-31 |
2023-08-12 |
rat |
| David McLaughlin, Emmanouella Tsirimonaki, George Vallianatos, Nikolaos Sakellaridis, Theofanis Chatzistamatiou, Catherine Stavropoulos-Gioka, Aspasia Tsezou, Ioannis Messinis, Dimitra Mangour. Stable expression of a neuronal dopaminergic progenitor phenotype in cell lines derived from human amniotic fluid cells. Journal of neuroscience research. vol 83. issue 7. 2006-07-25. PMID:16555279. |
further analysis showed strong expression of en-1, c-ret, ptx3, and nurr1 essential for induction and survival of midbrain dopaminergic neurons, th, aadc, and vmat2 components of dopamine synthesis and secretion, and syntaxin1a and snap-25 necessary for neurotransmitter exocytosis. |
2006-07-25 |
2023-08-12 |
human |
| Jackalina M Van Kampen, Christopher B Eckma. Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 27. 2006-07-25. PMID:16822985. |
the small molecule neurotransmitter dopamine has been shown to regulate cell cycle in developing and adult brain, and the d3 receptor is known to play an important role in dopaminergic development. |
2006-07-25 |
2023-08-12 |
rat |
| Shaik Shavali, Colin K Combs, Manuchair Ebad. Reactive macrophages increase oxidative stress and alpha-synuclein nitration during death of dopaminergic neuronal cells in co-culture: relevance to Parkinson's disease. Neurochemical research. vol 31. issue 1. 2006-07-20. PMID:16475001. |
parkinson's disease (pd) is characterized by progressive degeneration of dopaminergic neurons and a substantial decrease in the neurotransmitter dopamine in the nigro-striatal region of the brain. |
2006-07-20 |
2023-08-12 |
mouse |
| Ulrich Ott, Martin Reuter, Juergen Hennig, Dieter Vait. Evidence for a common biological basis of the Absorption trait, hallucinogen effects, and positive symptoms: epistasis between 5-HT2a and COMT polymorphisms. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 137B. issue 1. 2006-05-30. PMID:15965969. |
based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that absorption is associated with the val158met polymorphism of the catechol-o-methyltransferase (comt) gene affecting the dopaminergic neurotransmitter system. |
2006-05-30 |
2023-08-12 |
human |
| Anita Thapar, Michael O'Donovan, Michael J Owe. The genetics of attention deficit hyperactivity disorder. Human molecular genetics. vol 14 Spec No. 2. 2006-05-23. PMID:16244326. |
in contrast, evidence from pharmacological, neuroimaging and animal studies has suggested the involvement of specific neurotransmitter systems, notably dopaminergic pathways, in adhd and these aetiological clues have inspired a fruitful application of the candidate gene association approach. |
2006-05-23 |
2023-08-12 |
Not clear |
| R Ceravolo, A Antonini, D Volterrani, C Rossi, S Goldwurm, E Di Maria, L Kiferle, U Bonuccelli, L Murr. Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. Neurology. vol 65. issue 12. 2006-04-14. PMID:16380622. |
they found evidence of preserved presynaptic nigrostriatal function, suggesting that parkinsonism in the x fragile premutation might be related to postsynaptic dopaminergic changes or different neurotransmitter alterations. |
2006-04-14 |
2023-08-12 |
Not clear |
| Takuya Shinjo, Masakuni Okad. [Olanzapine use in cancer patients for refractory vomiting]. Gan to kagaku ryoho. Cancer & chemotherapy. vol 33. issue 3. 2006-04-03. PMID:16531716. |
olanzapine,indicated for schizophrenia in japan, has an affinity for multiple neurotransmitter receptors including dopaminergic, serotonergic, histaminergic, adrenergic and muscarinic receptors. |
2006-04-03 |
2023-08-12 |
Not clear |
| Katsuhiko Sakamoto, Cuimei Liu, Manami Kasamatsu, P Michael Iuvone, Gianluca Tosin. Intraocular injection of kainic acid does not abolish the circadian rhythm of arylalkylamine N-acetyltransferase mRNA in rat photoreceptors. Molecular vision. vol 12. 2006-03-31. PMID:16518309. |
recent studies have suggested that retinal dopaminergic neurons contain a circadian pacemaker, and dopamine is the neurotransmitter that drives circadian rhythmicity in the mammalian retina. |
2006-03-31 |
2023-08-12 |
rat |